Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study

Polo, Virginia Abello; Mantilla, William; Idrobo, Henry; Sossa, Claudia; Salazar, Luis A.; Peña, Ángela María; Herrera, Juan Manuel; Guerrero, Paola; Espinosa, Daniel; Quintero-Vega, Guillermo Enrique; Munevar, Isabel; Gálvez, Kenny; Henao, A.; Gomez, Rigoberto; Saavedra, José Domingo; Gaviria, Lina; Osuna, Mónica; Mateos, María Victoria

doi:10.1016/j.clml.2021.12.009

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present results show that the incidence of PC and MM was significantly higher in French Guiana than in mainland France or in other Latin American countries. Moreover, striking facts were the female preponderance and its recent increase, observations that are contrary to the usual predominance of MM in males [ 2 , 3 , 14 , 15 , 16 ]. The median age was substantially younger in French Guiana than in France [ 14 ].…”

Section: Discussionmentioning

confidence: 97%

The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana

Imounga,

Drak Alsibai,

Plenet

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: The objective was to review a decade of plasmacytoma (PC) and multiple myeloma (MM) data from French Guiana, and to study its spatial and temporal trends. Methods: This was a retrospective study of MM and PC between January 2005 and December 2014 using cancer registry data, including age-standardized incidence and mortality rates. Results: There were 110 cases of PC and MM (62 women and 48 men), representing the eighth most frequent malignancy in French Guiana. PC and MM were much more common in females. In men, 79% of cases occurred at ≥55 years, and in women, 90% of cases occurred at ≥50 years. The median age at diagnosis was 60 years for men and 66 years for women, while it was 72 years for men and 75 years for women in mainland France. The incidence rate standardized to the world population was 5.9 patients of PC and MM per 100,000 men/year and 7.8 per 100,000 women/year. Conclusions: In our territory, the incidence of PC and MM was higher and patients were diagnosed at a substantially younger age than in mainland France. Women had a greater incidence than men, and there was an increasing temporal trend of incidence among women. African ancestry and the frequency of obesity, notably among women, could have contributed to this observation.

show abstract

Section: Discussionmentioning

confidence: 97%

The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana

Imounga,

Drak Alsibai,

Plenet

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Multiple myeloma in Latin America: A systematic review

de Moraes Hungria,

Peña,

Gómez‐Almaguer

et al. 2024

eJHaem

View full text Add to dashboard Cite

The incidence of multiple myeloma (MM) has surged globally, particularly in Latin American countries, and is attributable to an aging population and increased life expectancy. This systematic review analyzes the epidemiology, patient characteristics, and treatment outcomes for MM in selected Latin American countries: Brazil, Mexico, Colombia, Argentina, Chile, Peru, and Uruguay. PubMed and the Latin American and Caribbean Health Sciences Literature (LILACS), conference abstracts (between June 2019 and June 2022), and GLOBOCAN registry (January 2010 to June 2022) were electronically searched. Qualitative analysis employed the Joanna Briggs Institute's critical appraisal tool. Among the 586 screened articles, 26 met the inclusion criteria. The participants’ median age ranged from 54 to 67 years. GLOBOCAN data revealed that for MM, Brazil and Uruguay had the highest and lowest incidence, 5‐year prevalence, and mortality, respectively. Immunoglobulin G was the most common subtype detected. Stage III was frequently diagnosed. Though many approved drugs are available and bispecific antibodies hold promise as a future therapy, limited access, especially for CAR‐T cell‐based therapy remains a concern. The incidence of MM is increasing in Latin America. Resource constraints and costs hinder access to novel drugs and regimens. Understanding disease patterns and patient characteristics is vital to improve MM management in these countries.

show abstract

Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21

Lim,

Reynolds,

Quach

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryIn Australia, bortezomib‐based induction (V‐IND) is used in >90% of newly diagnosed transplant‐eligible multiple myeloma (MM) patients. Four cycles of V‐IND with bortezomib–cyclophosphamide–dexamethasone or bortezomib–lenalidomide–dexamethasone are available via the Pharmaceutical Benefits Scheme prior to autologous stem cell transplantation (ASCT). Patients who demonstrate suboptimal response or who are refractory to V‐IND demonstrate inferior survival, representing a subgroup of MM where an unmet need persists. We evaluated an early, response‐adapted approach in these patients by switching to an intensive sequential therapeutic strategy incorporating daratumumab–lenalidomide–dexamethasone‐based (DRd) salvage, high‐dose melphalan ASCT followed by DRd consolidation and R maintenance. The overall response rate following four cycles of DRd salvage was 72% (95% credible interval: 57.9–82.4); prespecified, dual, Bayesian proof‐of‐concept criteria were met. Euro‐flow minimal residual disease (MRD) negativity was 46% in the intention‐to‐treat population and 79% in the evaluable population following 12 cycles of DRd consolidation. At the 24‐month follow‐up, median progression‐free survival and overall survival were not reached. DRd salvage was well tolerated with grade 3 and 4 events reported in 24% and 8% respectively. Response‐adapted DRd combined with ASCT achieves high rates of MRD negativity and durable disease control in this functional high‐risk group.

show abstract

Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study

Cited by 5 publications

References 31 publications

The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana

The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana

Multiple myeloma in Latin America: A systematic review

Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21

Contact Info

Product

Resources

About